Where does the data come from?

openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list). Official record: https://dps.fda.gov/drugshortages

Sanofi-Aventis U.S. LLC: Enoxaparin Sodium Injection to be discontinued

Q: How to monitor Sanofi-Aventis U.S. LLC and peer hematology records

DrugShortagePulse lists new DrugShortagePulse records from openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list) as they are published; a free weekly email digest and paid alerts follow records like this one.

Sanofi-Aventis U.S. LLC: Enoxaparin Sodium Injection to be discontinued. Its amount of 24 is top-decile (99th percentile of 353 records). Dated 16 days ago, it is in the active follow-up window. Score 60/100. As of 2026-11-04, from openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list).

Data as of 2026-11-04 · Compiled by Zalwin from openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list)

amount: 24 · 99th percentile of 353 DrugShortagePulse records · 8.0x the median

Free preview: all 12 published fields of this record are shown below. Locked: 352 related DrugShortagePulse records and the 5-column CSV export.

Field	Value
Manufacturer	Sanofi-Aventis U.S. LLC
Drug	Enoxaparin Sodium Injection
Dosage form	Injection
Therapeutic category	Hematology
Status	To Be Discontinued
Stage	Manufacturer discontinuation
Presentations affected	24
Package NDCs	0075-8020-10, 0075-8014-10, 0075-0624-30, 0075-0622-80, 0955-1006-10, 0955-1003-10, 0075-0626-03, 0075-8016-10, 0955-1008-10, 0075-8013-10, 0955-1016-01, 0955-1012-10, 0075-8018-10, 0075-2912-01, 0075-0621-60, 0075-8030-01, 0075-2915-01, 0955-1010-10, 0075-8022-10, 0075-0623-00
Manufacturer supply note	Discontinuation of the manufacture of the drug for the U.S. market. This decision is not related to product safety or quality concerns. FDA-approved generic enoxaparin products and other treatment options are available. Remaining inventory may continue to be available through wholesalers and other distribution channels until existing supplies are depleted. Availability may vary by presentation wit
Discontinued date	2026-10-20
First posted	2026-10-20
Updated	2026-10-20
amount percentile	99th of 353 (median 3, 8.0x median)
Peer records CSV (353 records)	🔒 Click to unlock →
CRM-ready export with official source URLs	🔒 Click to unlock →

View the official record

Markdown version

Watch Sanofi-Aventis U.S. LLC

Free email alert. Alert me when this company gets a new filing, lien, permit, contract or expiry in this feed. One confirmation email; unsubscribe any time.

Free for 1 company. More companies from $9/mo (25), $49/mo (500 + CSV), $199/mo (500 + CSV + API). Cancel any time from the link in every email.

Unlock Sanofi-Aventis U.S + all 353 records (CSV)

Instant CSV download · Card, Apple Pay, Google Pay or Link via Stripe · No account required
CSV columns: Manufacturer · Drug · Stage · Availability · Updated · official source URL

Source agency: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list)
Record date: 2026-10-20
Data refreshed: 2026-11-04
Refunds on request within 14 days

Search all records free →

Top DrugShortagePulse records: Fresenius Kabi USA, LLC · Hospira, Inc., a Pfizer Company · Fresenius Kabi USA, LLC · Hospira, Inc., a Pfizer Company · Vantive US Healthcare LLC · Browse all by state and category →

LIVE PUBLIC DATA Source: openFDA drug shortages endpoint (U.S. Food and Drug Administration drug shortage list) · Last refreshed: Wed, 04 Nov 2026 06:10:12 GMT

Is this your business? Add a "Listed on Zalwin" badge to your site

Paste this snippet into your website. It links to this public record; nothing is tracked on your site.

<a href="https://zalwin.com/report/drugshortagepulse/drugshort-sanofi-aventis-u-s-llc%7Cenoxaparin-sodium-injection%7Cto-be-discontinued" rel="noopener"><img src="https://zalwin.com/badge/listed.svg" alt="Sanofi-Aventis U.S. LLC on Zalwin public records" width="150" height="28"></a>

60 / 100 Score

The manufacturer is leaving the market.
Sterile injectable: hospital and 503B demand.

What is the DrugShortagePulse record for Sanofi-Aventis U.S. LLC?

Sanofi-Aventis U.S. LLC's Enoxaparin Sodium Injection is on the FDA drug shortage list. Manufacturer discontinuation. Last updated 2026-10-20.

How does Sanofi-Aventis U.S. LLC compare to other DrugShortagePulse records?

This is a top-decile record: its amount of 24 is 8.0x the median of 3 across 353 records. It is 16 days old, still within a typical 45-day follow-up window.

Sanofi-Aventis U.S. LLC vs. top 3 peers

Organization	Amount	Percentile	Record date
Sanofi-Aventis U.S. LLC	24	99th	2026-10-20
Baxter Healthcare	3	62nd	2026-10-30
Baxter Healthcare	2	49th	2026-10-30
Baxter Healthcare	2	49th	2026-10-30

How to monitor Sanofi-Aventis U.S. LLC and peer hematology records

Get new DrugShortagePulse records like Sanofi-Aventis U.S. LLC by email (free, weekly)

We email one confirmation link now; the weekly digest starts only after you confirm. One-click unsubscribe in every email.

Double opt-in: nothing is sent until you click the confirmation link. One-click unsubscribe.

See this week's digest

Get new shortages in your categories

DrugShortagePulse emails new and changed FDA drug shortages matching your therapeutic categories.

See plans

✓ Read-only, live public data · Key and unlock right after payment · Card, Apple Pay, Google Pay or Link via Stripe · Refunds on request within 14 days

From the openFDA drug shortages endpoint, which mirrors the FDA drug shortage list and can lag it by days. Availability and recovery notes are the manufacturer's own statements to FDA. Company and product level only. Verify with FDA and the manufacturer before acting.